TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01356069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SB-APP
Description: SB-APP, derived from Brief-Adlerian Psychodynamic Psychotherapy (B-APP) is a time-limited (40 weekly sessions) psychodynamic psychotherapy based on Alfred Adler's theory and delivered in sequential and repeatable modules.~SB-APP is focused specifically on four personality functioning levels (PFL). These are assessed by the therapists on the basis of symptoms, quality of interpersonal relationships, overall social behaviors, cognitive and emotional patterns, and defense mechanisms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators.
Study: NCT03547427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM
Description: Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CGM
Description: Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM
Description: Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen test
Description: Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen
Study: NCT01555099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: oral inhaled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: oral inhaled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral inhaled
Study: NCT03547427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetaminophen test
Description: Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen
Study: NCT03759743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LMT1-48
Description: capsules containing Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules that did not contain any probiotics
Study: NCT03868397

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver MRI
Description: Liver MRI including 4D flow sequence is performed twice in liver transplantation recipients, before and 1 month-after transplantation.~In donor candidates, liver MRI including 4D flow sequence is performed twice in 1-3 weeks to assess repeatability of the technique.
Study: NCT02541565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03332758

Intervention type: PROCEDURE
Intervention: Pars plana vitrectomy
Description: Standard of care treatment for retinal detachment, macular hole, or epiretinal membrane.

Intervention type: PROCEDURE
Intervention: Pars plana vitrectomy
Description: Standard of care treatment for retinal detachment, macular hole, or epiretinal membrane.

Intervention type: PROCEDURE
Intervention: Pars plana vitrectomy
Description: Standard of care treatment for retinal detachment, macular hole, or epiretinal membrane.

Intervention type: PROCEDURE
Intervention: External drainage
Description: Standard of care treatment for retinal detachment.
Study: NCT02968225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Game
Description: The game involves viewing subtle nonverbal behaviors of game characters for the purpose of executing their own goal-directed behavior in the game related to solving various crimes. The learning involves interpreting nonverbal cues on the animated characters, such as pointing, head turns, eye gaze cues.
Study: NCT02466516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: SEL tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: SEL tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: SEL tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: SEL tablet administered orally once daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIM
Description: Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIM
Description: Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIM
Description: Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly
Study: NCT01332058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: 8 possible weeks of motivational interviewing sessions
Study: NCT00720421

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 1 mg oral 2 capsules

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 Placebo oral 2 capsules

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 Placebo oral 2 capsules

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 Placebo oral 2 capsules

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 Placebo oral 2 capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam
Description: Lorazepam 1 mg oral 2 tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam
Description: Lorazepam 1 mg oral 2 tablets
Study: NCT00431275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: CP-675,206 15 mg/kg iv single dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: CP-675,206 15 mg/kg iv single dose on Day 1
Study: NCT02902718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mē
Description: The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.
Study: NCT03827616

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated IMRT using helical Tomotherapy.
Description: 70 Gy in 28 fractions intensity-modulated radiotherapy (IMRT)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated IMRT using helical Tomotherapy.
Description: 60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.
Study: NCT02759770

Intervention type: OTHER
Intervention: no intervention
Description: This is a clinical observational study, no intervention was included.

Intervention type: OTHER
Intervention: no intervention
Description: This is a clinical observational study, no intervention was included.

Intervention type: OTHER
Intervention: no intervention
Description: This is a clinical observational study, no intervention was included.
Study: NCT00720421

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam
Description: Lorazepam 1 mg oral 2 tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam
Description: Lorazepam 1 mg oral 2 tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam
Description: Lorazepam Placebo oral 2 tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam
Description: Lorazepam Placebo oral 2 tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam
Description: Lorazepam Placebo oral 2 tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam
Description: Lorazepam Placebo oral 2 tablets
Study: NCT04414696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: eHealth exercise intervention for postpartum women at increased risk of depression
Study: NCT03671382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Training Program and Patient Prompt Sheet
Description: The intervention being delivered is a two-component intervent. First component is the Oncologist Communication Skills Training Program. This is an e-learning module teaching oncologists to recognize and respond to patient/caregiver distress, provide information including prognosis and discuss goals of care. The second component is a patient prompt sheet which will be administered to three patients of intervention arm oncologists in the waiting area at least 30 minutes before their consultation. The sheet includes structured questions for patients to ask the oncologist about diagnosis and prognosis and will prompt patients to label and express their emotions in a direct manner.
Study: NCT03125876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT053PTSA
Description: receive oral CT053PTSA once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
Study: NCT01478399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB1023 Injection
Description: 90 mg Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB1023 Injection
Description: 90 mg Dose
Study: NCT02262234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Program Type 1
Description: The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Program Type 2
Description: The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
Study: NCT03136367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Option Grid
Description: The Option Grid(TM) encounter decision aid for early stage breast cancer surgery is a one-page, evidence-based summary of available options presented in a tabular format.
Study: NCT01898637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Augmented pulse oximetry using incentive spirometer.
Description: Augmented pulse oximetry using incentive spirometer.

Intervention type: DEVICE
Group type: OTHER
Intervention: Incentive spirometer.
Description: The incentive spirometer is a simple passive device that measures the amount of air a person can inhale.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incentive spirometer.
Description: The incentive spirometer is a simple passive device that measures the amount of air a person can inhale.
Study: NCT04546815

Intervention type: DRUG
Intervention: Daptomycin
Description: According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.
Study: NCT03547427

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen test
Description: Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetaminophen test
Description: Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin-induced hypoglycemia
Description: During insulin-induced hypoglycemia admission, subjects will receive an insulin bolus(s) dosed to reach blood sugar of less than 55 mg/dL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia
Description: During insulin-induced hypoglycemia admission, subjects will receive an insulin bolus(s) dosed to reach blood sugar of less than 55 mg/dL.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise-induced hypoglycemia
Description: During exercise-induced hypoglycemia admission, subjects participate in three 15 minute exercise bouts (45 minutes total) to lower blood sugar to less than 55 mg/dL.
Study: NCT03136367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Picture Option Grid
Description: The Picture Option Grid was derived from the Option Grid for early stage breast cancer. It uses the same evidence and integrates images and simpler text, thus exploiting pictorial superiority. The Picture Option Grid has been specifically designed for women of lower SES and low health literacy.
Study: NCT03328585

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I in person
Description: 6 weeks of CBT-I in person, one 1-hour long session per week
Study: NCT00390793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT04780035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
Description: The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)
Description: The use of placebo: intramuscularly twice, given 21 to 28 days apart at a dose of 0.5 ml
Study: NCT03379740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: Subject's own e-cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: Subject's own e-cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P4M3-1.7%
Description: P4M3 e-liquid concentration of 1.7% nicotine without lactic acid
Study: NCT03547427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-induced hypoglycemia
Description: During exercise-induced hypoglycemia admission, subjects participate in three 15 minute exercise bouts (45 minutes total) to lower blood sugar to less than 55 mg/dL.
Study: NCT03379740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P4M3-1.7%
Description: P4M3 e-liquid concentration of 1.7% nicotine without lactic acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P4M3-1.7%LA
Description: P4M3 e-liquid concentration of 1.7% nicotine with lactic acid
Study: NCT04209556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 100 mg QD
Description: Investigational Product
Study: NCT03379740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P4M3-1.7%LA
Description: P4M3 e-liquid concentration of 1.7% nicotine with lactic acid
Study: NCT03328585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I via Telemedicine
Description: 6 weeks of CBT-I via telemedicine, one 1-hour long session per week

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Patients in this arm will receive no intervention but will receive CBT-I treatment after conclusion of the study
Study: NCT02180217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osilodrostat
Description: Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LCI699 matching placebo
Description: Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.
Study: NCT03379740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P4M3-3%LA
Description: P4M3 e-liquid concentration of 3% nicotine with lactic acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P4M3-3%LA
Description: P4M3 e-liquid concentration of 3% nicotine with lactic acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P4M3-4%LA
Description: P4M3 e-liquid concentration of 4% nicotine with lactic acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P4M3-4%LA
Description: P4M3 e-liquid concentration of 4% nicotine with lactic acid
Study: NCT04209556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 300 mg QD
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 600 mg QD
Description: Investigational Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-6826647 400 mg QD
Description: Investigational Product
Study: NCT00333619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonpharmacological sleep intervention
Description: The intervention combines: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
Study: NCT02033109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC-1005
Description: Intravaginal use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC gel
Study: NCT01606124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given PO
Study: NCT02032225

Intervention type: OTHER
Intervention: Skin biopsy
Study: NCT01606124

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02370758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir or Ganciclovir
Study: NCT03475524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN 1000 Mg Oral Tablet
Description: oral tablet 1ooomg systemic metformin will be given to group
Study: NCT03753048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Y-Graft
Description: Y-Graft Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, the left internal thoracic artery is cut off distally and the right internal thoracic artery is cut off proximally and distally. Then they anastomose the following way. Left internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, distal part of the right internal thoracic artery should be anastomosed to the obtuse marginal artery. Finally, proximal part of the right internal thoracic artery is anastomosed to the left internal thoracic artery as Y-graft in the end to side fashion. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-Situ
Description: In-Situ Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, both internal thoracic arteries are cut off distally. Then they anastomose the following way. Right internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, left internal thoracic artery should be anastomosed to the obtuse marginal artery. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
Study: NCT02875470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intensiv Perio Set
Description: Diamond burs for root planing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gracey curette
Study: NCT03475524

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: oral placebos will be given to control beside trichloracetic acid peeling

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trichloroacetic Acid Peeling
Description: Trichloroacetic acid peeling to the three groups
Study: NCT01348165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 137882
Description: Powder for oral solution